GENE ONLINE|News &
Opinion
Blog

2025-04-14|

Generic Drug Stability Testing: ICH Guidelines Ensure Consistent Framework Across Regions

by Mark Chiang
Share To

NEWSFLASH

Pharmaceutical manufacturers conduct stability testing of generic drugs to ensure patient safety and meet regulatory requirements. Key elements of this testing include adherence to international guidelines, developing robust testing protocols, managing and analyzing data, and maintaining regulatory compliance. Generic drug manufacturers follow the International Conference on Harmonisation (ICH) guidelines, which provide a framework for consistent stability testing across different regions. Furthermore, manufacturers develop specific stability testing protocols that identify the critical quality attributes (CQAs) of the drug product. These protocols also determine the appropriate testing methods and the frequency of testing. They also manage and analyze the resulting data, using statistical methods to interpret the results and make informed decisions about the drug product’s stability. Staying up-to-date with Good Manufacturing Practice (GMP) regulations and specific regional requirements is another necessary component for regulatory compliance.

Newsflash | Powered by GeneOnline AI
Date: April 14, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
LATEST
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio
2026-03-13
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
Dividend Exchange Rate for Q3 2025 Announced by DEC on March 12, 2026
2026-03-12
NewHydrogen Files International Patent Application for ThermoLoop Technology to Enhance Hydrogen Production Efficiency
2026-03-12
BioGene Therapeutics Inc. Appoints Raj S. Pruthi as Director
2026-03-12
Scroll to Top